...
机译:使用能力网络协作和决策分析模型评估干扰素α-2b加利巴韦林作为德国慢性丙型肝炎的初始治疗的成本效益
Institute for Technology Assessment and Department of Radiology Massachusetts General Hospital Harvard Medical SchoolMGH Institute for Technology Assessment Harvard Medical SchoolProgram on Health Technology Assessment and Decision Sciences Institute of Medical Informatics Biometry and Epidemiology University of Munich;
Institute for Technology Assessment and Department of Radiology Massachusetts General Hospital Harvard Medical SchoolProgram on Health Technology Assessment and Decision Sciences Institute of Medical Informatics Biometry and Epidemiology University of Munich;
Alfried Krupp von Bohlen und Halbach-Chair for Medical Management University of Duisburg-Essen;
Centre for Health Economics and Health System Research University of Hanover;
Health Outcomes Research Group Robert Koch Institute;
Alfried Krupp von Bohlen und Halbach-Chair for Medical Management University of Duisburg-Essen;
Department for Epidemiology and Health Reporting Robert Koch Institute;
Department of Medical Psychology University Hospital Hamburg-Eppendorf University of Hamburg;
Centre for Health Economics and Health System Research University of Hanover;
Division of Clinical Decision Making Department of Medicine Tufts–New England Medical Center Tufts University School of Medicine;
Department of Internal Medicine General Hospital;
Chronic hepatitis C; Interferon α-2b; Ribavirin; Cost-effectiveness analysis; Competence network collaboration;
机译:使用能力网络协作和决策分析模型评估干扰素α-2b联合利巴韦林作为德国慢性丙型肝炎的初始治疗的成本效益
机译:聚乙二醇干扰素α2a与干扰素α2b加利巴韦林联用作为慢性丙型肝炎患者初始治疗的生活质量,工作效率和医疗资源利用的比较。
机译:聚乙二醇干扰素α-2b联合利巴韦林作为瑞典慢性丙型肝炎的初始治疗的成本效益。
机译:HLA-C基因在丙型肝炎病毒中感染埃及患者,估计HLA-C基因和干扰素/利巴韦林与丙型肝炎病毒治疗的关系
机译:接受聚乙二醇干扰素和利巴韦林抗病毒治疗的慢性丙型肝炎退伍军人依从性的含义。
机译:聚乙二醇干扰素α-2b加利巴韦林相对于干扰素α-2b加利巴韦林在慢性丙型肝炎初始治疗中的成本效益
机译:alfapeguinterferon-2a和利巴韦林与alfapeguinterferon-2b和利巴韦林:慢性丙型肝炎基因型1治疗的成本效益和预算影响评估α-聚乙二醇化干扰素(2a和2b)和利巴韦林治疗慢性丙型肝炎,基因型1:a成本效益分析